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Ambulatory ECG (holter)Abstract Background: Sarcoidosis is a multisystem disease characterized histologically by the for-
mation of granulomas in many tissues. In many cases, cardiac involvement may be clinically silent
but in others it may be the only clinical feature. Sudden death has been reported in 12–65% of car-
diac sarcoidosis cases, and is usually attributed to malignant ventricular arrhythmias. We assessed
the prevalence of cardiac arrhythmias in patients with sarcoidosis not complaining from cardiac
symptoms aiming for early detection of cardiac involvement.
Methods: Fifteen patients with sarcoidosis (either thoracic or extrathoracic) were enrolled in the
current study. Clinical diagnosis was based on tissue biopsy. All patients were symptoms free as
regards their cardiac condition. Standard ECG was done for detection of bundle branch block
(BBB), or atrioventricular block. 24 h ambulatory ECG (holter) was done to detect significant prema-
ture beats (>10/h), runs of supraventricular or ventricular tachycardia (>3 beats), or ventricular fib-
rillation. Echocardiographic examination was done for assessment of left and right ventricle systolic
and diastolic function and significant segmental wall motion abnormalities (SWMA) (>2 segments).
All patients were under steroid therapy. Patients with a history of Ischemic heart disease, previous
myocardial infarction (MI), congestive heart failure, electrolyte abnormalities, and patients with pre-
viously implanted permanent pacemakers or cardiac defibrillators were excluded from the study.
Results: Mean age of the study group was 49.6 ± 10.4 including 9 females and 6 male patients.
Resting ECG was abnormal in 3 (20%) cases. Six patients (40%) had diastolic dysfunction however
LV and RV systolic function and resting SWM were normal. No significant bradyarrhythmias were
observed during holter monitoring however significant tachyarrhythmias including frequent prema-
ture atrial and ventricular beats, runs of non-sustained SVT and VTwere observed in 5 patients. Life-
threatening sustainedVTwas observed in a single patient that requiredRadiofrequency (RF) ablation
followed by ICD implantation.
Conclusions: Holter monitoring provides a useful, convenient and inexpensive mean of non-
invasive screening for cardiac involvement in sarcoidosis especially in patients without cardiac symp-
toms. Extended holter should be a part of the routine work-up of any patient with sarcoidosis. Theycardia;
quency.
rculosis.
312 M.A. Abdelhamid, H.S. Diabexact effect of steroid therapy on the arrhythmia burden remains a matter of debate. Cardiac MRI
should be done to all patients with sarcoidosis having either abnormal symptoms or abnormal basic
screening tools especially abnormal holter.
 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of The Egyptian Society of Chest
Diseases and Tuberculosis. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Table 1 Clinical and demographic features among the study
group.
Items Mean ± SD/frequency






Dry cough 11 (73%)
Wheezy chest 7 (46%)
Palpitations 1 (6.6%)
Tissue biopsy
Med. LN. biopsy by mediastinoscope 10 patients (66.6%)
Lung biopsy through thoracotomy 3 patients (20%)
Skin lesion biopsy 2 patients (13.3%)
Med. LN.: Mediastinal lymph node.Introduction
Sarcoidosis is a multisystem disease characterized histologi-
cally by the formation of granulomas in many tissues.
The etiology of sarcoidosis remains unknown, although
infectious agents and environmental exposures have been
proposed [1].
Most patients present with pulmonary involvement of
whom approximately half are asymptomatic presenting by
hilar lymphadenopathy on chest X-ray [2]. Skin, followed by
hepatic, gastrointestinal, ocular, and neurological affection,
represents the commonest manifestation in decreasing order
of frequency. Cardiac involvement occurs only in 2–5% of
the cases and represents one of the least common manifesta-
tions [3–4].
However, survival with cardiac sarcoidosis has historically
been poor. Sudden death has been reported as the second most
common cause of mortality in patients with sarcoidosis in the
United States. In autopsy studies, cardiac involvement was
reported in up to 40–50% of patients [5–6]. Thus, it is likely
that cardiac sarcoidosis is commoner than clinically recog-
nized, although it remains a relatively uncommon disease [2].
In many cases cardiac involvement may be clinically silent
but in others it may be the only clinical feature. Heart block is
the most common arrhythmia, followed by bundle branch
block. Ventricular tachycardia is less common, and atrial
involvement alone is rare. Congestive heart failure occurs in
10–30%of cases. Suddendeath occurs in 12–65%of cardiac sar-
coidosis cases, and is usually attributed tomalignant ventricular
arrhythmias or complete heart block [7].
One of the main challenges for clinicians evaluating patients
with systemic sarcoidosis is determining when and how to
investigate for cardiac involvement. Owing to a low index of
suspicion, and in some cases lack of pulmonary involvement,
it may take many years before cardiac sarcoidosis is finally
diagnosed. This is regrettable as cardiac sarcoidosis is readily
treatable with corticosteroids, and because prompt diagnosis
and treatment may prevent severe complications such as left
ventricular dysfunction, heart failure, malignant arrhythmias,
and even death [8].
In this limited study we assessed the prevalence of cardiac
arrhythmias in patients with sarcoidosis (thoracic or extratho-
racic) not complaining from cardiac symptoms aiming for
early detection of cardiac involvement to prevent the occur-
rence of cardiac fibrosis that leads to fatal arrhythmias.
Patients and methods
Study population
Fifteen consecutive patients either admitted to general wards
or visited outpatient clinics of the chest department at AinUniversity hospitals during the period from April 2014 to
May 2015 were enrolled in the current study. Clinical
diagnosis of sarcoidosis in all cases was based on histopatho-
logical examination of tissue biopsy as shown in Table 1.
Patients with a history of Ischemic heart disease, previous
MI, congestive heart failure, electrolyte abnormalities, and
patients with implanted permanent pacemakers or cardiac
defibrillators were excluded from the study. Informed
consent was obtained from all patients. The study was
approved by the Research and Ethics Committee of the Chest
Department, Faculty of Medicine, Ain Shams University at
April 2014.
Methods
Detailed history and full clinical examination was done for all
patients with special emphasis on the presence of palpitation,
presyncope, or true syncope. Palpitations were considered sig-
nificant if the patients’ complaint lasted >2 weeks [9]. Serum
electrolyte and oxygen saturation assessment were done to
exclude other causes of arrhythmia.
Electrocardiogram (ECG)
Standard 12 lead ECG was done for recording of resting
abnormalities. Abnormal resting ECG was defined as the
presence of conduction defect as bundle branch block (BBB),
interventricular conduction delay (IVCD), or atrioventricular
block of any degree or any other arrhythmias (atrial or
ventricular) [7].
Arrhythmic burden in patients with sarcoidosis 313Holter monitoring
Twenty-four hours ambulatory ECG was done. Data were
analyzed by an experienced cardiologist. An abnormal Holter
recording was considered in the presence of significant prema-
ture ventricular contractions (PVCS) more than 10 per hour,
non-sustained ventricular tachycardia (VT) (>3 beats),
supraventricular tachycardia (SVT)(>3 beats), sustained VT,
or Ventricular fibrillation (VF) [10]. Follow up holter monitor-
ing was done one month after the start of medical therapy.
Echocardiography
Standard transthoracic echocardiographic examination was
performed on Vingmed Vivid 5 machine with a 2.5 MHz
transducer. Standard 2D echocardiographic views and
Doppler examination were used to assess LV and RV ejection
fraction (EF), diastolic LV function, and resting segmental
wall motion abnormalities (SWMA). Abnormal echo was
defined as the presence of Left ventricular dysfunction
(EF < 45%), significant SWMA (two or more segments),
RV ventricular systolic dysfunction in the absence of
pulmonary hypertension, significant diastolic dysfunction
inappropriate for age [11].
Statistical analysis
Data were collected, coded, tabulated, and then analyzed using
SPSS version 16 for Windows (SPSS Inc, Chicago, IL, USA).
Data were presented as mean (standard deviation) and fre-
quency (%) for numerical variables and categorical variables
respectively.Results
This study included 15 patients diagnosed as sarcoidosis pre-
senting to the chest department of Ain Shams University hos-
pitals. All the studied patients were presented by chest
symptoms without any cardiac symptoms except only for
one patient was complaining of frequent palpitation attacks
that were accompanied by mild dizziness 10 days before pre-
sentation. Clinical diagnosis was confirmed in all studied
patients by histopathological examination of tissue biopsy as
shown in Table 1. Demographic and clinical features are
shown in Table 1.
Electrocardiogram (ECG) and echocardiographic findings
According to predefined criteria resting ECG was abnormal in
3 patients. No bradyarrhythmias or AV blocks were observed
in the current study. BBB was observed in 2 patients (13%).
Frequent isolated PVCs up to ventricular bigeminy, ventricu-
lar couplets, non-sustained VTAC and even sustained VT were
observed in the third patient (Figs. 1–5).
All patients in the current study had normal LV and RV
systolic function and resting SWM. Mean EF was 63.4
± 4.8. LV diastolic dysfunction was observed in 6 cases
(40%) all of which were grade 1 (LV relaxation abnormality)
except in one case where pseudonormal pattern was observed
(grade 2 diastolic dysfunction).Ambulatory ECG monitoring (Holter)
24 h ambulatory ECG recording was done for 14 patients only.
The remaining patient had sustained VT in his resting ECG so
the patient was under continuous monitoring at CCU. Accord-
ing to predefined criteria abnormal holter recordings were
observed in 6 patients (40%). No significant bradyarrhythmias
or blocks were observed during holter monitoring.
On the other hand, a wide spectrum of tachyarrhythmias
was encountered in the study population ranging from fre-
quent PACS, and frequent PVCS, up to runs of SVT, non-
sustained VT, and even sustained VT (Table 2). Three (20%)
patients had infrequent PACS and PVCS. Six (40%) patients
had a totally free holter recording.
Only one patient in the current study (48 year old male)
gave a history of palpitation attacks (not meeting predefined
criteria for significant palpitation). ECG done at presentation
showed slow sustained VT at a rate of 100 beats/min. The
patient was vitally stable. Successful cardioversion was done
by amiodarone infusion followed by DC shock then mainte-
nance amiodarone infusion. However the attacks became more
frequent, more rapid with changing morphology not respond-
ing to all antiarrhythmic drugs including magnesium infusions
(Fig. 4). The patients’ echo and serum electrolytes were nor-
mal. Cardiac MRI imaging revealed 2 small enhanced foci
measuring 1.1 and 1.4 cm along the midportion of the inter-
ventricular septum (Fig. 5). The RV was totally normal show-
ing no fibrous or fatty replacement.
The patient underwent RF ablation using a 3D mapping
system (CARTO 3) to modify arrhythmia substrate that
resulted in reduction in VT burden followed by implantation
of dual chamber ICD. Another session of RF ablation was
done 3 months later at a center with epicardial mapping
facilities.
All the studied patients were under steroid therapy. Patients
with abnormal holter recordings started antiarrhythmic ther-
apy with class III agents (amiodarone and sotalol) and Ib
agents (mexiletine). Follow up holter recording showed com-
plete resolution of arrhythmias in 4 patients, reduction in
PVCs, and VT burden in the remaining patients.Discussion
Sarcoidosis is a granulomatous disease of unknown etiology.
Noncaseating granulomas are the pathological hallmark. Sar-
coidosis is a worldwide disease with a prevalence of about 4.7–
64 in 100,000 [12–13]. It occurs mostly (70%) in patients aged
25–45 years. In Europe and Japan, there is a second peak in
women older than 50 years. Sarcoidosis is rare in people
younger than 15 or older than 70 years [14–15]. The mean
age in this study group was 49.6 ± 10.6 years with a predom-
inant female gender (60% of the study group).
CS is associated with extremely poor prognosis, especially
once overt cardiac symptoms and signs develop [8]. The preva-
lence and risk of cardiac sarcoidosis (CS) differ across races:
the prevalence in African Americans is three times greater than
in Caucasians. CS is also more prevalent and more aggressive
in Japanese patients than in North American patients, with
higher case fatality rates [16].
One of the major challenges for clinicians evaluating
patients with systemic sarcoidosis is determining when and
Figure 1 BBB and isolated PVC recorded in 65 year old female patient with thoracic sarcoidosis.
Figure 2 Ventricular bigeminy (upper panel), and ventricular couplets (lower panel) in 48 year old male patient with thoracic
sarcoidosis.
Figure 3 Frequent atrial premature beats in 58 year old female patient with thoracic sarcoidosis (atrial trigeminy) (upper panel), SVT
run (mostly atrial fibrillation) in the same patient (lower panel).
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Figure 4 Sustained VT at a slow rate with inferior axis (upper panel) and sustained VT at a faster rate and a superior axis (lower panel)
denoting different tachycardia exit, in a 48 year old male patient with thoracic sarcoidosis.
Figure 5 Cardiac MRI images of the same patient showing enhanced foci at the interventricular septum.
Table 2 Ambulatory ECG findings (frequency of arrhyth-
mias) in the study population.
Normal holter 9 (60%)
Abnormal holter 6 (40%)
Frequent PACS 2 (13.3%)
Frequent PVCS 2 (13.3%)
Runs of SVT 1 (6.6%)
Non sustained VT 1 (6.6%)
Sustained VT 1 (6.6%)
Infrequent PACS 1 (6.6%)
Infrequent PVCS 2 (6.6%)
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Endomyocardial biopsy (EMB) remained for years the gold
standard for the diagnosis of CS. However, owing to the
patchy distribution of the disease, EMB specimens are pos-
itive in fewer than 25% of cases. CS involves mostly the freewall of the left ventricle and the interventricular septum,
while most EMB specimens are taken from the right ventri-
cle apex because it is more easily accessed [17].
In the current study we used 3 noninvasive tools namely
resting ECG, echocardiogram, and holter monitoring in 15
patients with sarcoidosis proven with tissue biopsy
aiming for early detection of cardiac involvement to prevent
the occurrence of cardiac fibrosis that leads to fatal
arrhythmias.
Resting ECG and echocardiography
ECG can reveal abnormalities in 60–75% of CS patients. The
most common manifestations in decreasing order of frequency
are complete heart block (due to involvement of the basal sep-
tum by granuloma), BBB, followed by ventricular then atrial
arrhythmias [7]. In the current study, only 20% of the patients
had abnormal ECG findings. This can be explained by the
absence of sure diagnosis of CS, in addition to limited number
316 M.A. Abdelhamid, H.S. Diabof patients enrolled, and the by the fact that, even patients with
CS may remain clinically silent for years.
Echocardiographic abnormalities can be seen in 14–56%
of patients with CS including LV systolic dysfunction,
SWMA, RV systolic dysfunction in the absence of pulmonary
hypertension, and/or significant diastolic dysfunction inap-
propriate for the patient’s age [7]. In the current study mean
EF was 63.4 ± 4.8% without SWMA. LV diastolic dysfunc-
tion was present in 40% of the study population which could
be attributed to the mean age of the study group rather than
a marker of cardiac affection. It is worth noting that MRI
revealed 2 foci of delayed enhancement affecting cardiac sep-
tum in 1 patient which is almost an exclusive feature of CS
[18–19].
24 Hour ambulatory ECG and the effect of conservative and
invasive treatment
Abnormal holter recordings were reported in up to 50% of
symptomatic patients with cardiac sarcoidosis with an overall
sensitivity and specificity ranging from 29% to 71% and 86%
to100% respectively [9]. Significant arrhythmias were
recorded in 40% of the current study population including
life threatening sustained VT in one patient despite that hol-
ter monitoring was done for 24 h only. It should be noted
that another 20% of the study population had infrequent
arrhythmias that did not meet the predefined criteria for
abnormal monitoring. 20% of the cases had atrial arrhyth-
mias including runs of SVT (atrial fibrillation) and 20%
had ventricular arrhythmias including runs of VT with
rapidly changing morphology denoting more than 1 focus
or more than 1 tachycardia exit. Several previous studies
reported that though CS tends to involve the atria less exten-
sively, atrial fibrillation can be the only presenting manifesta-
tion and that induced VT in those patients tends to have
more than 1 morphology [18–21].
All the patients of the current study were under steroid
therapy for their extracardiac condition. Patients with abnor-
mal holter findings were subjected to antiarrhythmic therapy
namely oral sotalol and amiodarone with excellent control of
arrhythmias as evidenced by follow up holter done one month
after starting therapy. A single patient was refractory to med-
ical treatment. Similar data about the success of class 3 antiar-
rhythmic agents in patients with CS were previously reported
[22]. On the other hand while some studies reported on the
beneficial role of immunosuppression in the control of arrhyth-
mias others failed to show benefit [23–24]. Furthermore, wors-
ening of ventricular arrhythmias has been reported with
corticosteroid therapy possibly due to aneurysm formation
[20,25,26]. It seems that treatment with prednisone is effective
only in early stages of the disease before the development of
overt clinical cardiac symptoms [27].
Rf ablation was done in one patient in the current study
that resulted only in a decrease in the frequency of the VT
attacks. The patient underwent another session at another cen-
ter with capability of epicardial mapping that eliminated the
tachycardia. The second session was driven by multiple shocks
experienced by the patient from his ICD. Variable data about
ablation outcomes were reported ranging from complete elim-
ination of VT, reduction in VT burden, to recurrences in most
patients [22,28].To sum up the above data, it is clear that the above screen-
ing methods have relatively high sensitivity, but none of the
abnormalities they identify is highly specific for CS (low
specificity) [29]. The main role of these noninvasive tests in
our opinion is to identify people at high risk of development
of future events particularly in the presence of symptoms
that could not be attributed to the extracardiac condition
(recurrent syncope, progressive dyspnea, serious ventricular
arrhythmias).
Smedema and colleagues reported that asymptomatic
patients with no abnormalities on baseline screening tests did
not experience any cardiac complications over an approximate
2 year period, and hence require no further cardiac investiga-
tions apart from annual follow up. On the other hand, patients
with cardiac symptoms (especially palpitations) or significant
abnormalities on any of these 3 basic tools should be consid-
ered candidates for cardiac MRI [30].
This study had some limitations; Relatively small number
of the patients enrolled. A longer period of holter monitoring
might be required to show more incidence of arrhythmias than
detected particularly bradyarrhythmias being the most com-
monly encountered in this patients category. Cardiac sarcoido-
sis was confirmed by MRI only in a single patient who had
incessant tachycardia due to limited feasibility and the excel-
lent response to classical antiarrhythmic therapy. Routine
MRI in the other patients with positive ECG or holter findings
might have increased the diagnostic yield of the current study.
Conclusions
Cardiac arrhythmias are common even in asymptomatic
patients with sarcoidosis. Holter monitoring provides a useful,
convenient and inexpensive means of noninvasive screening for
cardiac involvement in sarcoidosis especially in patients with-
out cardiac symptoms. Extended holter monitoring should
be a part of the routine work up for any patient with sarcoido-
sis. The exact effect of steroid therapy on the arrhythmia bur-
den remains a matter of debate that needs further studies.
Cardiac MRI should be done to all patients with sarcoidosis
having either abnormal symptoms or abnormal basic screening
tools especially abnormal holter.
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